In Brief: Palomar Medical Technologies/Coherent
This article was originally published in The Gray Sheet
Executive Summary
Palomar Medical Technologies/Coherent: Ink definitive agreement under which Coherent gains exclusive distribution rights to Palomar's EpiLaser laser-based hair removal systems in the U.S., Far East and "most countries in Europe," Palomar says. Under terms of the agreement, Coherent pays $3.5 mil. up front for the distribution rights, "a license to key patents relating to hair removal," and a three-year warrant to purchase shares of Palomar common stock with an exercise price of $5.25 per share. Coherent, with 200 direct sales reps, will be responsible for sales, marketing, service, training and education under the deal, for which the two companies signed a letter of intent in September ("The Gray Sheet" Nov. 3, p. 11)...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.